Get the Stockscreener App
0.1239
7.47%
-0.010
Pre-market:
.12
-0.0039
-3.15%
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study - Marketscreener.com
Hemispherx Biopharma stock hits 52-week low at $0.12 By Investing.com - Investing.com South Africa
Hemispherx Biopharma stock hits 52-week low at $0.12 - Investing.com
AIM ImmunoTech Inc. Announces Dosing of First Subject in Phase 2 Trial of Ampligen Combined with Imfinzi for Late-Stage Pancreatic Cancer - Nasdaq
AIM Doses First New Subject in Phase 2 Study of Ampligen - GlobeNewswire
Can This Dual-Drug Approach Transform Pancreatic Cancer Treatment? AIM Moves Clinical Trial Forward - StockTitan
AIM stock touches 52-week low at $0.13 amid market challenges - MSN
CEO & President Equels Thomas K acquire 20,000 shares of AIM ImmunoTech Inc [AIM] - Knox Daily
AIM ImmunoTech advances Ampligen for avian influenza vaccine - MSN
Hemispherx BioPharma Issues Press Release on Phase 2 Study Collaboration - Defense World
AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire
Hemispherx BioPharma Postpones Offering Pending Annual Report Filing - Defense World
Understanding AIM’s book value per share for better investment insights - US Post News
AIM ImmunoTech Releases Virtual Investor "What This Means Segment” - The Manila Times
AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen® and Imfinzi® in Late-Stage Pancreatic Cancer - Nasdaq
AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - GlobeNewswire
AIM ImmunoTech announces that it will not proceed with an - GlobeNewswire
AIM ImmunoTech Delays Capital Raise: Key Details on S-1 Offering Postponement - StockTitan
The Potential Rise in the Price of AIM ImmunoTech Inc (AIM) following insiders activity - Knox Daily
AIM's Pancreatic Cancer Trial Milestone: Zero Severe Side Effects, Phase 2 Gets Green Light - StockTitan
AIM ImmunoTech Inc (AIM) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Balance Sheet Dive: AIM ImmunoTech Inc (AIM)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
AIM ImmunoTech announces a planned follow-up clinical study - GlobeNewswire
AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist - TipRanks
AIM ImmunoTech advances Ampligen for avian influenza vaccine By Investing.com - Investing.com Nigeria
AIM ImmunoTech Inc. Initiates Plan to Advance Ampligen as Vaccine Adjuvant for Avian Influenza - Nasdaq
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks - The Manila Times
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu - StockTitan
AIM ImmunoTech Inc (AIM) Has Recovered -14.29% From Its Low: Is This The Beginning Of A Trend? - Stocks Register
Stocks of AIM ImmunoTech Inc (AIM) are poised to climb above their peers - SETE News
Erasmus Medical Center Safety Committee Grants Approval to - GlobeNewswire
AIM ImmunoTech Advances Phase 2 DURIPANC Trial Of Ampligen And Imfinzi For Pancreatic Cancer - Nasdaq
AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2 - TipRanks
Investing in AIM ImmunoTech Inc (AIM) might be a great opportunity, but the stock is a bit undervalued - US Post News
Breakthrough in Pancreatic Cancer Treatment: Clinical Trial Shows 15-Month Disease Stability - StockTitan
Daily Progress: AIM ImmunoTech Inc (AIM) Drop -8.07, Closing at 0.19 - The Dwinnex
AIM’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
AIM ImmunoTech (NYSE:AIM) Stock Price Down 8.1% – What’s Next? - Defense World
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019 - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Marketscreener.com
AIM ImmunoTech Announces Publication of Final Clinical - GlobeNewswire
AIM ImmunoTech's Ampligen Shows Breakthrough Results in Long COVID Fatigue Treatment Trial - StockTitan
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - GlobeNewswire
Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance
AIM ImmunoTech's Ampligen Shows Breakthrough Results for Long COVID and ME/CFS Treatment - StockTitan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Allegion Plc (ALLE-N) QuotePress Release - The Globe and Mail
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewswire
AIM ImmunoTech Advances Ampligen Cancer Programs, Reports Strong Clinical Progress Across Pipeline - StockTitan
Mesoblast (NASDAQ:MESO) versus AIM ImmunoTech (NYSE:AIM) Head-To-Head Contrast - Defense World
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):